Over the course of previous decades, worldwide research has continued to be focused on increasingly sophisticated novel methods for the development of chiral building blocks.
Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.
Newsletter & e-edition
News, trends and background information as well as the latest issue of CHEManager International